EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study

Hui Yang, Zhaojian Wang, Chunguo Jiang, Yi Zhang, Ying Zhang, Man Xu, Yi Zhang, Yushu Wang, Xuefeng Liu iD, Zhuoling An, Zhaohui Tong iD

Journal of Medical Virology · 2023

DOI: 10.1002/jmv.28947 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medical Virology, 2023. Verfasst von Hui Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Azvudine is recommended by Chinese health authorities for COVID‐19 treatment but has not been tested in real‐world clinical studies. This study aimed to evaluate the real‐world effectiveness of Azvudine among COVID‐19 nonhospitalized patients. This was a retrospective cohort study, looking at nonhospitalized patients who tested positive for SARS‐CoV‐2. Patients admitted between December 19, 2022 and January 5, 2023 were included. Those who received Azvudine treatment were in the Azvudine group, while those who received supportive treatment were the control group. The primary outcome was the disease progression rate by Day 28. Secondary outcomes were individual disease progression outcomes (death or COVID‐19‐related hospitalization) and duration of fever. The safety outcomes were assessed based on adverse events (AEs) overall, as well as AEs that were considered to be related to the drug. A total of 804 patients with high risk for progression were enrolled in our study. Among them, 317 (39.43%) received treatment with Azvudine. Our study found that Azvudine could reduce the rate of disease progression, as well as rate of COVID‐19‐related hospitalization in patients comparing the control group. Furthermore, if taken within 3 days of the onset of symptoms, it could also shorten the duration of fever. Despite a higher incidence of drug‐related AEs compared to supportive treatment, the majority of these were mild. Azvudine has been found to be effective in reducing the rate of disease progression of COVID‐19, albeit with a slight increase in AEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansAdultSARS-CoV-2COVID-19 Drug TreatmentRetrospective StudiesTreatment OutcomeDisease ProgressionAzidesDeoxycytidine

Stichwörter der Autor:innen

AzvudineCOVID-19effectiveness and safetyreal-world study

Substanzen

azvudineAzidesDeoxycytidine

Autor:innen und Institutionen

  • Department of Pharmacy, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China.
  • Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Beijing Institute of Respiratory Medicine, Capital Medical University, Beijing, China.
  • Departments of Pathology, Urology, and Radiation Oncology, The Ohio State University, Columbus, Ohio, USA.

ORCID-Profile: Xuefeng Liu, Zhaohui Tong

Zitieren

APA

Yang, H., Wang, Z., Jiang, C., Zhang, Y., Zhang, Y., Xu, M., Zhang, Y., Wang, Y., Liu, X., An, Z., & Tong, Z. (2023). Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study. Journal of Medical Virology. https://doi.org/10.1002/jmv.28947

Vancouver

Yang H, Wang Z, Jiang C, Zhang Y, Zhang Y, Xu M, et al. Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study. Journal of Medical Virology. 2023. doi:10.1002/jmv.28947

BibTeX
@article{Yang2023,
  author = {Yang, Hui and Wang, Zhaojian and Jiang, Chunguo and Zhang, Yi and Zhang, Ying and Xu, Man and Zhang, Yi and Wang, Yushu and Liu, Xuefeng and An, Zhuoling and Tong, Zhaohui},
  title = {Oral azvudine for mild‐to‐moderate COVID‐19 in high risk, nonhospitalized adults: Results of a real‐world study},
  journal = {Journal of Medical Virology},
  year = {2023},
  doi = {10.1002/jmv.28947}
}
Kostenlos starten →